Myomo

Myomo Debt/EBITDA

The Total Debt to EBITDA Ratio of Myomo (MYO) as of Oct 29, 2026 is -1.33. In the previous year, Total Debt to EBITDA Ratio was -1.31 — a change of 1.52% (lower).

Debt/EBITDA

-1.33

YoY

1.52%

Last updated:

Total Debt to EBITDA Ratio of Myomo is 2025 -1.33 . Total Debt to EBITDA Ratio of Myomo was 2024 -1.31 . It decreases by 1.52% lower compared to the previous year.

The Myomo Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-0.13 USD
Jan 1, 2019
-0.25 USD
Jan 1, 2020
-0.02 USD
Jan 1, 2021
-0.07 USD
Jan 1, 2022
-0.05 USD
Jan 1, 2023
-0.07 USD
Jan 1, 2024
-1.31 USD
Jan 1, 2025
-1.33 USD
The Myomo Debt/EBITDA history
YEARDebt/EBITDAYoY
-1.33+1.52%
-1.31+1,687.91%
-0.07+40.74%
-0.05-27.38%
-0.07+356.99%
-0.02-93.64%
-0.25+96.50%
-0.13+1,950.88%
-0.01-99.63%
-1.67+187.21%
-0.58+14.34%
-0.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myomo Stock analysis

What does Myomo do? Myomo, Inc. generates revenue by selling its MyoPro product line, which consists of myoelectric-controlled upper limb braces designed for patients with neuromuscular disorders. The company directly sells these orthoses to patients and bills their insurance providers for coverage. The MyoPro enables users to control partially paralyzed limbs using their own muscle signals, supporting daily activities like eating and dressing. The target market includes adults and adolescents with conditions such as stroke, spinal cord injury, and brachial plexus injury. The MyoPro product line is marketed as a solution for functional improvement in upper limb paralysis, focusing on home and community use. Myomo’s devices are positioned to help patients regain independence in daily living tasks. Insurance reimbursement is a key revenue stream, with the company handling billing directly to insurers on behalf of patients. The primary customer segments are individuals with neuromuscular conditions requiring orthotic support for upper limb functionality. Myomo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myomo stock

Total Debt to EBITDA Ratio of Myomo is -1.33 in 2025.

Total Debt to EBITDA Ratio of Myomo changed from -1.31 to -1.33, representing a 1.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Myomo since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Myomo with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Myomo

All Key Metrics — Myomo